MediciNova Granted Rights To Use BC-PIV For SARS-CoV-2 Vaccine Joint Development

(RTTNews) - MediciNova, Inc. (MNOV) has reached a deal with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.

BioComo is a biotech company founded at Mie Prefecture Japan in May 2008. BC-PIV is the core platform technology which was named after the corporate name, BioComo.

MediciNova has been granted exclusive worldwide development rights to use BC-PIV for SARS-CoV-2 vaccine development from BioComo and Mie University.

Shares of MediciNova were up more than 10% in pre-market trade on Monday.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More